Journal Watch · Journal of Allergy and Clinical Immunology · 2026

CXCL16 as a potential therapeutic target to limit the activity of asthmatic CD4 memory T cells.

This implies a role of the chemokine in sustaining local antigen presentation and correlates with CXCL16 expression being found in human asthmatic lung macrophages, monocytes, and dendritic cells.<h4>Conclusion</h4>CXCL16 blockade may regulate allergen-induced CD4 Trm cell accumulation and persistence in the lungs, suggesting a potential therapeutic approach for asthma.

Sethi GS, Croft MJournal of Allergy and Clinical Immunology3 min readPharma relevance 50/100

DOI: 10.1016/j.jaci.2026.05.004PMID: 42134609Study type: preclinical (animal / model) study

TL;DR

This implies a role of the chemokine in sustaining local antigen presentation and correlates with CXCL16 expression being found in human asthmatic lung macrophages, monocytes, and dendritic cells.<h4>Conclusion</h4>CXCL16 blockade may regulate allergen-induced CD4 Trm cell accumulation and persistence in the lungs, suggesting a potential therapeutic approach for asthma.

Key findings

  • This implies a role of the chemokine in sustaining local antigen presentation and correlates with CXCL16 expression being found in human asthmatic lung macrophages, monocytes, and dendritic cells.<h4>Conclusion</h4>CXCL16 blockade may regulate allergen-induced CD4 Trm cell accumulation and persistence in the lungs, suggesting a potential therapeutic approach for asthma.

Numbers at a glance (from the abstract)

50%70%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

This protective effect persisted, with reduced numbers of lung CD4 Trm cells being visualized over time, and was evident during subsequent asthma exacerbations shown by a tolerogenic effect with continued marked reduction in lung inflammation. Late blockade of CXCL16 after allergen exposure also resulted in fewer Trm cells, an effect reproduced by blocking antigen presentation but not by inhibiting T-cell trafficking into the lung.

Full abstract (original)

Background: <h4>Background</h4>The C-X-C motif chemokine receptor CXCR6 is considered a marker of some tissue-resident memory T (Trm) cells, but its importance in controlling lung CD4 Trm cells in asthma remains unclear.<h4>Objective</h4>We explored the involvement of CXCL16-CXCR6 interactions in the activity and accumulation of CD4 Trm cells relevant to lung inflammatory disease.<h4>Methods</h4>Human and murine asthmatic lung CD4 T cells were analyzed by single-cell transcriptomics to assess CXCR6 expression, and the effects of blocking the CXCL16-CXCR6 pathway were then evaluated using a disease model.<h4>Results</h4>Single-cell RNA sequencing of human and murine asthmatic lung cells revealed elevated CXCR6 mRNA expression in CD4 T cells. Confirming a role for CXCR6, short-term blockade of its ligand, CXCL16, during repeated intranasal allergen challenges in the mouse reduced the accumulation of lung CD4 memory effector T cells by 50% to 70%, coincident with decreased tissue inflammation.

What they did: This protective effect persisted, with reduced numbers of lung CD4 Trm cells being visualized over time, and was evident during subsequent asthma exacerbations shown by a tolerogenic effect with continued marked reduction in lung inflammation. Late blockade of CXCL16 after allergen exposure also resulted in fewer Trm cells, an effect reproduced by blocking antigen presentation but not by inhibiting T-cell trafficking into the lung.

Results & conclusions: This implies a role of the chemokine in sustaining local antigen presentation and correlates with CXCL16 expression being found in human asthmatic lung macrophages, monocytes, and dendritic cells.<h4>Conclusion</h4>CXCL16 blockade may regulate allergen-induced CD4 Trm cell accumulation and persistence in the lungs, suggesting a potential therapeutic approach for asthma.

Abstract © the authors / Journal of Allergy and Clinical Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jaci.2026.05.004 · PubMed 42134609.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Journal of Allergy and Clinical Immunology study find?

This implies a role of the chemokine in sustaining local antigen presentation and correlates with CXCL16 expression being found in human asthmatic lung macrophages, monocytes, and dendritic cells.<h4>Conclusion</h4>CXCL16 blockade may regulate allergen-induced CD4 Trm cell accumulation and persistence in the lungs, suggesting a potential therapeutic approach for asthma.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Allergy and Clinical Immunology in 2026. This protective effect persisted, with reduced numbers of lung CD4 Trm cells being visualized over time, and was evident during subsequent asthma exacerbations shown by a tolerogenic effect with continued marked reduction in lung inflammation.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jaci.2026.05.004. PubMed ID: 42134609. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Sethi GS, Croft M. CXCL16 as a potential therapeutic target to limit the activity of asthmatic CD4 memory T cells.. Journal of Allergy and Clinical Immunology (2026). DOI: 10.1016/j.jaci.2026.05.004.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cxcl16-as-a-potential-therapeutic-target-to-limit-the-activity-of-asthma-605004/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides